Q-omics provides the consensus-scored FBXO16 profile across patient tissues and cancer cell-line models. FBXO16 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FBXO16 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, FBXO16 RNA expression shows 16,739 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KICH as cancer lineages where FBXO16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO16 survival associations across molecular data types. FBXO16 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO16 RNA expression–survival associations across cancer types. High FBXO16 expression shows unfavorable associations in KIRP, HNSC, KICH and LIHC, but favorable associations in COAD and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KIRP as the clearest survival context for FBXO16 RNA expression.
This table summarizes FBXO16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO16 shows lower tumor expression in KICH and THCA and higher tumor expression in LUAD, KIRP, COAD and UCEC. The KICH box plot shows higher FBXO16 RNA expression in normal versus tumor tissue (log2 FC = −1.440, t-test p < 0.001).
This table shows molecular features associated with FBXO16 in patient tissues and cancer cell lines. In patient samples, FBXO16 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
